List of Excipients in Branded Drug MEMBERS MARK OMEPRAZOLE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sam's West Inc	MEMBERS MARK OMEPRAZOLE	omeprazole	68196-303	ASCORBIC ACID
Sam's West Inc	MEMBERS MARK OMEPRAZOLE	omeprazole	68196-303	CELLULOSE, MICROCRYSTALLINE
Sam's West Inc	MEMBERS MARK OMEPRAZOLE	omeprazole	68196-303	CETYL ALCOHOL

Member’s Mark Omeprazole Excipient Strategy and Commercial Opportunities

Last updated: September 19, 2026

Member’s Mark omeprazole is an OTC private-label proton pump inhibitor positioned against Prilosec OTC and other omeprazole delayed-release products. Its commercial value depends less on active-ingredient differentiation than on excipient control, enteric protection, capsule or tablet manufacturability, stability, retail cost, and supply continuity. The strongest opportunities are lower-cost delayed-release systems, improved moisture protection, smaller pack formats, and differentiated products for adherence and gastrointestinal tolerability.

What is Member’s Mark omeprazole?

Member’s Mark omeprazole is a Sam’s Club private-label OTC product containing omeprazole, generally marketed in a 20 mg delayed-release dosage form. Omeprazole is acid-labile and must be protected from gastric degradation before release in the intestine. The product therefore requires an enteric delivery system, usually through coated pellets, granules, mini-tablets, or an enteric-coated tablet.

The Member’s Mark brand does not identify a single formulation, manufacturer, FDA application, or patent estate. Private-label OTC products can be sourced from different contract manufacturers over time, and the applicable inactive ingredients depend on the specific National Drug Code, dosage form, and supplier.

Attribute	Commercial assessment
Active ingredient	Omeprazole
Typical strength	20 mg
Dosage form	Delayed-release capsule, tablet, or equivalent multiparticulate system
Regulatory category	OTC omeprazole product marketed under an FDA-approved application or applicable OTC pathway
Primary technical requirement	Protection from gastric acid and moisture
Main competitors	Prilosec OTC, store-brand omeprazole, esomeprazole, lansoprazole
Primary buyer	Retail consumer through warehouse-club distribution
Main cost drivers	Enteric polymer, coating process, capsule or tablet production, packaging, stability testing, and distribution

What excipients are likely used in Member’s Mark omeprazole?

The excipient strategy for an omeprazole delayed-release product normally includes a core, an isolation or seal coat, an enteric coat, and a protective outer layer. Exact composition must be confirmed against the current product label and inactive-ingredient statement for the relevant NDC.

Core excipients

Typical core materials include:

• Sugar spheres or microcrystalline cellulose starter cores
• Omeprazole
• Lactose or another diluent
• Povidone or hydroxypropyl cellulose as a binder
• Crospovidone or another disintegrant
• Magnesium oxide or an alkaline stabilizer
• Talc or colloidal silicon dioxide as a processing aid

An alkaline microenvironment is important because omeprazole is unstable under acidic conditions. Magnesium oxide and related buffering agents can improve chemical stability in the drug-containing layer. The amount and location of alkaline excipient affect dissolution, stability, coating performance, and capsule fill weight.

Seal-coat excipients

The seal coat separates the omeprazole-containing layer from the acidic enteric polymer. It can contain hypromellose, hydroxypropyl cellulose, povidone, talc, or other film-forming and anti-tacking materials.

A robust seal coat reduces the risk of interaction between the active ingredient, alkaline stabilizer, and enteric polymer. It also improves mechanical durability during coating, filling, transport, and storage.

Enteric-coat excipients

Common enteric systems use methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, or related polymers. Plasticizers such as triethyl citrate or polyethylene glycol can reduce brittleness. Talc or equivalent anti-tacking agents improve coating efficiency.

The enteric layer must resist dissolution in the stomach and release omeprazole at the intended intestinal pH. The key performance tests are acid resistance, buffer-stage dissolution, assay, degradation products, and stability.

Capsule and color-system excipients

Hard gelatin or hypromellose capsule shells may contain titanium dioxide, colorants, gelatin, and water. Capsule selection affects moisture transmission, appearance, consumer acceptance, and compatibility with the pellet system.

A capsule-based product can carry multiparticulate pellets without exposing the product to the compression forces used for tablets. Tablets may reduce packaging and filling costs but require careful control of compression, coating defects, friability, and dose uniformity.

How should excipients be optimized for Member’s Mark omeprazole?

The best excipient program should optimize the entire dosage form rather than minimize the unit price of each ingredient.

1. Prioritize alkaline stability

Omeprazole degradation is a central formulation risk. The product should maintain a controlled alkaline microenvironment around the active ingredient. Candidate stabilizers should be screened for:

• Assay retention
• Sulfone and sulfide degradation products
• Moisture sensitivity
• Compatibility with coating polymers
• Effect on dissolution
• Impact on capsule fill weight

Magnesium oxide can be commercially attractive because it is widely available and inexpensive. Its particle size, grade, dispersion, and loading level can affect blend uniformity and dissolution.

2. Reduce moisture ingress

Moisture protection is one of the highest-value areas for formulation improvement. Opportunities include:

• Higher-barrier blister packaging
• Desiccant-enabled bottles
• Induction seals
• Moisture-resistant capsule shells
• Improved outer film coatings
• Lower residual moisture in coated pellets

For a warehouse-club product, packaging economics matter because large-count bottles increase the duration of consumer storage after opening. A high-barrier bottle or blister may add packaging cost but reduce stability failures and product returns.

3. Improve enteric-coating efficiency

Enteric polymers are a significant processing cost. A formulation developer can lower cost by improving polymer dispersion, reducing coating weight without compromising acid resistance, increasing solids content, or adopting a more efficient fluid-bed coating process.

The target is not the lowest coating weight. It is the lowest validated coating weight that consistently meets acid-stage and buffer-stage dissolution specifications across scale-up, equipment changes, and normal manufacturing variability.

4. Evaluate multiparticulate alternatives

Multiparticulate omeprazole can be produced as coated pellets, granules, or mini-tablets. Each platform has a different commercial profile.

Platform	Advantages	Commercial limitations
Coated pellets in capsules	Strong dose uniformity and flexible coating control	More processing steps and higher coating cost
Enteric-coated mini-tablets	High payload flexibility and potential packaging efficiency	More demanding compression and coating control
Enteric-coated tablets	Lower capsule-related costs and simple branding	Higher risk of coating damage during compression
Granules in sachets	Flexible administration and pediatric potential	More complex consumer use and packaging

For the current warehouse-club model, capsules or delayed-release tablets remain the most straightforward formats. Mini-tablets may offer the best long-term platform if the manufacturer can control coating uniformity and scale.

What commercial opportunities exist beyond the current product?

Lower-cost private-label supply

Omeprazole has a mature active pharmaceutical ingredient supply base and extensive generic manufacturing experience. A supplier can compete through:

• Lower coating-material consumption
• Faster fluid-bed processing
• Higher batch yield
• Reduced rejects from coating defects
• Common excipient platforms across multiple customers
• Dual sourcing of polymers and capsule shells

The private-label market rewards delivered cost, fill rate, and consistent quality. A technically superior formulation has limited value if it cannot support warehouse-club volumes.

Larger-count and subscription formats

Warehouse-club customers are receptive to 42-, 84-, and 100-count formats. Larger packs can reduce per-unit packaging costs and increase shelf productivity. The formulation must support an extended in-use period after opening, which makes moisture-barrier packaging commercially important.

Potential extensions include:

• 14-count starter packs
• 42-count standard packs
• 84- or 100-count value packs
• Calendar blister packaging
• Travel-size packaging
• Multipacks with antacid products

Consumer-friendly dosage forms

Potential differentiation includes:

• Smaller capsules
• Easier-to-swallow tablets
• Lower-fill-weight multiparticulates
• Products designed for consumers who have difficulty swallowing
• Flavor-masked granules or sachets
• Packaging that supports once-daily adherence

A flavored or sprinkle formulation could reach consumers who do not prefer conventional capsules. It would also introduce new stability, taste-masking, dose-uniformity, and packaging requirements.

Pediatric and adolescent opportunities

Omeprazole products for younger patients may use oral suspensions, granules, or dispersible dosage forms. Commercial development would require age-appropriate dosing, palatability, stability after reconstitution, and labeling consistent with the applicable FDA pathway.

This is a higher-complexity opportunity than a conventional adult OTC capsule. It may justify a premium only if the product obtains a clear regulatory and clinical positioning.

What FDA regulatory issues affect Member’s Mark omeprazole?

Omeprazole OTC products require compliance with FDA labeling, manufacturing, quality, and postmarket requirements. The applicable pathway depends on the specific product and FDA application.

Key regulatory issues include:

• Drug Facts labeling
• Delayed-release dissolution specifications
• Assay and degradation-product limits
• Stability under long-term and accelerated conditions
• Content uniformity or dosage-unit uniformity
• Residual solvents and elemental impurities
• Microbial quality
• Container-closure integrity
• Inactive-ingredient suitability
• Change-control documentation for contract manufacturing

FDA’s OTC monograph reforms under the CARES Act changed the regulatory structure for many OTC products. A company cannot assume that the commercial label alone establishes the product’s exact legal pathway. Product-specific FDA records, labeling, and NDC data control the analysis.[1]

What patents protect omeprazole products?

The original compound and early omeprazole patent rights expired years ago. Current commercial exposure generally comes from formulation, delivery, manufacturing, or method-of-use rights rather than basic composition-of-matter protection.

Formulation patents

Potentially relevant claim categories include:

• Enteric-coated pellets
• Stabilized omeprazole particles
• Alkaline core compositions
• Specific polymer combinations
• Delayed-release tablets
• Moisture-protective dosage forms
• Multiparticulate delivery systems

A formulation patent matters only if its claims cover the actual commercial composition or process. Broad historical patent families may have expired, been narrowed, or become irrelevant to a current private-label formulation.

Method-of-use patents

Omeprazole method-of-use rights may cover treatment of acid-related disorders, dosing schedules, or specific patient populations. For a conventional OTC product, method-of-use exposure is usually less important than formulation and regulatory compliance because the consumer label must remain within the authorized indication.

Manufacturing patents

Manufacturing-related claims may cover pellet layering, enteric coating, polymer dispersion, drying, or process controls. These rights can create supplier-level barriers even where the finished product has no meaningful composition patent protection.

What is the Orange Book status of Member’s Mark omeprazole?

The Member’s Mark brand name alone is insufficient to identify an Orange Book listing. The Orange Book is organized around FDA application and product information, not retail branding. A private-label product may be associated with an ANDA or NDA held by the manufacturer or sponsor rather than by Sam’s Club or the Member’s Mark brand.

For commercial diligence, the relevant records are:

1. The exact NDC.
2. The FDA application number.
3. The application holder.
4. The dosage form and strength.
5. Listed patents and exclusivity.
6. Current marketing status.
7. Any therapeutic-equivalence designation.

A standard generic omeprazole product typically has limited remaining market exclusivity because omeprazole is a mature generic ingredient. The practical barrier is usually manufacturing qualification, regulatory compliance, retail access, and reliable supply rather than patent exclusion.[2]

Are Paragraph IV challenges relevant to Member’s Mark omeprazole?

Paragraph IV litigation is generally relevant when a generic applicant challenges an unexpired patent listed for an approved reference drug. For a mature OTC omeprazole private-label product, the principal risk is usually not a new Paragraph IV challenge against the Member’s Mark label. The relevant exposure may sit with the underlying application holder, the reference product, or a supplier’s formulation technology.

A Paragraph IV review should examine:

• Listed patents for the underlying FDA application
• Certification history
• Notices of paragraph IV certification
• Patent litigation under the Hatch-Waxman Act
• Any 30-month stay
• Settlement terms
• Authorized-generic arrangements

A brand owner or generic supplier can also face litigation based on non-Orange-Book patents, including process or formulation patents. Those disputes may not produce the same regulatory stay as an Orange Book patent challenge.

Which companies compete with Member’s Mark omeprazole?

The competitive set includes:

• Procter & Gamble’s Prilosec OTC
• Amazon Basic Care
• CVS Health private label
• Walgreens private label
• Walmart and other retail private labels
• Perrigo and other OTC contract manufacturers
• Generic prescription omeprazole suppliers
• Esomeprazole and lansoprazole brands and generics

The closest commercial competitors are other 20 mg delayed-release omeprazole products. Esomeprazole competes through a different active ingredient and brand positioning, while lansoprazole competes through an alternative proton pump inhibitor platform.

Product segment	Main competitive lever
Branded omeprazole	Consumer recognition and advertising
Warehouse-club private label	Price, count size, and supply reliability
Retail private label	Shelf placement and promotional pricing
Prescription generic	Pharmacy access and reimbursement
Esomeprazole	Ingredient differentiation and perceived potency
Lansoprazole	Alternative PPI positioning

How strong is the patent estate for Member’s Mark omeprazole?

The patent estate is likely weak at the brand level and stronger at the supplier and process level. Omeprazole’s basic active-ingredient protection is expired. A defensible commercial position would instead depend on:

• A proprietary coating process
• A low-cost, high-yield manufacturing method
• Improved stability in large-count packaging
• A differentiated dosage form
• A formulation patent with claims aligned to the product
• Manufacturing know-how that is difficult to replicate
• Regulatory history and supplier qualification

Trade secrets may have more practical value than patents for coating parameters, pellet-layering conditions, polymer dispersion, drying profiles, and moisture-control procedures.

What generic launch risks exist?

A new entrant could launch a competing omeprazole product if it obtains the required FDA authorization and meets manufacturing standards. The main launch risks are:

• Failure of acid-stage dissolution
• Inadequate long-term stability
• Moisture-related degradation
• Coating defects
• Batch-to-batch dose variability
• Inactive-ingredient incompatibility
• Packaging failure
• Contract-manufacturer capacity constraints
• Retail qualification delays
• Price erosion from multiple private-label suppliers

Patent risk is usually secondary to execution risk. A supplier with a lower-cost formula can still lose the opportunity if it cannot maintain quality at warehouse-club volume.

What licensing and partnership opportunities exist?

The most practical opportunities are commercial and technical rather than molecule-focused. Potential structures include:

• Private-label supply agreements
• Contract manufacturing with formulation transfer
• Exclusive regional distribution
• Coating-process licensing
• Dual-source agreements for enteric polymers
• Co-development of pediatric or sprinkle formats
• Packaging partnerships for high-barrier bottles or blisters

A licensing agreement should define ownership of formulation improvements, process changes, stability data, regulatory filings, supplier qualifications, and post-termination manufacturing rights. The party controlling the FDA application and supporting chemistry, manufacturing, and controls dossier has the strongest negotiating position.

Key Takeaways

• Member’s Mark omeprazole is a mature OTC private-label product with limited active-ingredient patent risk.
• The central technical problem is protecting acid-labile omeprazole from gastric degradation and moisture-driven instability.
• The highest-value excipient levers are alkaline stabilization, enteric-polymer efficiency, seal-coat integrity, and moisture control.
• Warehouse-club commercial opportunities center on large-count packs, lower delivered cost, supply reliability, and extended in-use stability.
• The precise Orange Book and patent position requires review of the product’s NDC and underlying FDA application.
• Formulation, process, and manufacturing patents may matter more than expired compound patents.
• Trade secrets involving coating and drying parameters can create stronger practical barriers than broad legacy patents.
• Pediatric, sprinkle, dispersible, and packaging-led extensions offer the clearest opportunities for meaningful differentiation.

FAQs

Does Member’s Mark omeprazole use the same excipients as Prilosec OTC?

Not necessarily. Both products require acid protection and delayed release, but they may use different alkaline stabilizers, enteric polymers, binders, capsule shells, coating weights, and packaging systems.

Can a company reformulate Member’s Mark omeprazole without changing the active ingredient?

Yes, but a formulation change may require regulatory submission, stability data, dissolution data, process validation, and updated inactive-ingredient documentation. The required filing depends on the underlying FDA application and the scale of the change.

Is omeprazole suitable for a liquid OTC formulation?

Omeprazole is technically challenging in liquid form because it is acid-labile and sensitive to environmental conditions. A liquid or suspension product requires effective stabilization, dose uniformity, palatability, and post-opening stability.

Are enteric polymers the main cost in omeprazole manufacturing?

They are an important cost, but total economics also depend on coating time, yield, labor, equipment utilization, capsule filling, packaging, stability failures, and rejected batches. Reducing polymer use without preserving dissolution performance can increase total cost.

Can a new omeprazole product obtain meaningful patent protection?

Yes, but protection is more likely to arise from a specific formulation, delivery system, manufacturing process, or stability improvement than from omeprazole itself. Claim scope must correspond closely to the commercial product.

References

1. U.S. Food and Drug Administration. (2023). Over-the-counter monograph reform under the Coronavirus Aid, Relief, and Economic Security Act. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (2024). DailyMed: Omeprazole delayed-release products. National Library of Medicine.

5. U.S. Food and Drug Administration. (2024). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.